Concepedia

Author

Tanya Jindal

University of California, San FranciscoORCID

Also Known As

T. Jindal, Tanya Jindal

56

Publications

332

Citations

9

H-Index

15

Concepts

All Affiliations

University of California, San FranciscoUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of WashingtonFred Hutch Cancer CenterCleveland Clinic
TJ

About

Tanya Jindal is an author at University of California, San Francisco specializing in cancer therapeutics, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

56

2

Cancer Therapeutics

3

3

56

3

Health Sciences

2

2

30

4

Diagnostic Sciences

2

2

30

5

Pathology

1

1

14

Tanya Jindal

×

9

Publications

217

Citations

9

H-Index

YearCitations

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Vadim S. Koshkin, Nicholas Henderson, Marihella James,

Cancer

2021

80

Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience

Dimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin,

Clinical Genitourinary Cancer

2023

26

Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Dimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder,

Clinical Genitourinary Cancer

2022

22

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

Joseph J. Park, Alec Chu, Jinju Li,

JCO Precision Oncology

2024

19

Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

Amanda Nizam, Tanya Jindal, Cindy Jiang,

Journal of Clinical Oncology

2024

16

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer

Divya Natesan, Li Zhang, Henry J. Martell,

Frontiers in Oncology

2022

15

Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

Tanya Jindal, Cindy Jiang, Omar Alhalabi,

Journal of Clinical Oncology

2024

14

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

Tanya Jindal, Xiaolin Zhu, Rohit Bose,

Frontiers in Oncology

2023

13

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin

Tanya Jindal, Li Zhang, Prianka Deshmukh,

Clinical Genitourinary Cancer

2023

12

Page 1